Moneycontrol
HomeNewsBusinessWelspun One to invest Rs 900 crore to develop 110-acre warehousing park near Mumbai
Trending Topics

Welspun One to invest Rs 900 crore to develop 110-acre warehousing park near Mumbai

The company plans to develop 30 acre to 100 acre Grade A warehousing parks cross India

July 06, 2020 / 18:53 IST
Story continues below Advertisement
Representative Image

Welspun One Logistics Parks has launched its maiden 110 acre Grade A warehousing park with a leasable area of 3.2 million square feet and an estimated investment of Rs 900 crore in Bhiwandi in Mumbai Metropolitan Region (MMR).

The project is located on prime land with clear legal title, fully owned by the promoters of Welspun Group. The 110 acre project in Bhiwandi entails an estimated investment of Rs 900 crore and has a potential leasable area of approximately 3.2 mn sq ft.

Story continues below Advertisement

Welspun One has also entered into a memorandum of understanding (MoU) with the Maharashtra state government under the Magnetic Maharashtra Initiative. It is in advanced stages of receiving necessary approvals under the state’s Integrated Logistics Parks (ILP) policy. This development is expected to create upwards of 2,700 multi-level job opportunities.

With pre-construction planning and design already in place, the park will be operational by Q4 2021.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show